HDAC3 and gout: Although there has been lacking of studies about HDAC3 inhibitor to challenge with MSU crystals-induced gouty inflammation in vivo, the identification of the anti-inflammatory role of HDAC3 deficiency may provide valuable clues for the future applications of selective HDAC3 inhibitor in gout patients.